Also listed under Skin Diseases
ClinicalTrials.gov term: Scleroderma, Systemic
Scleroderma clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
17 trials changed in the last 30 days: 1 stopped, 11 with notable changes, 5 with minor changes only.
- Minor: ROSY-S · Rollover Study · Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment Trial sites expanded: 153 → 166 locations
- Minor: Ianalumab · Diffuse Cutaneous Systemic Sclerosis Trial sites reduced: 106 → 96 locations
-
Minor: 2 trials marked Unknown by the registry's verification sweep Changed
- Minor: BAH242 · Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor: RAISE · Rare AutoImmune SElf-management Programme Development Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Notable: Hyaluronidase Injections for Sclerodactyly · Scleroderma Primary endpoint(s) modified
- Notable: Healthy Adult Participants and · Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body Primary endpoint(s) modified
- Notable: Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images Primary and study completion pushed from Jul 2026 to May 2027
- Notable: AURORA · AZD0120 in Autoimmune Diseases Phase changed: Phase 1 → Phase 1/2
- Notable: UVA-1 · Skin Tightening and Improvement of Hand Function in Scleroderma Results posted: Nov 2, 2026
- Minor: NKX019 · Immune-Mediated Diseases (Ntrust-2) Trial sites reduced: 18 → 12 locations
- Notable: hiPSSS · Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs) Recruitment opened
- Notable: ATTRACT · ATG-201 · Autoimmune Diseases Recruitment opened
- Notable: Patient Reported Outcomes With UVA-1 Therapy · Sclerosing Skin Diseases Primary and study completion pushed from Jun 2026 to Jun 2027
- Notable: YTS109 Cell Injection · Recurrent/Refractory Autoimmune Disease Primary and study completion dates pushed to Apr 21, 2027
- Notable: CRT-402 in Refractory Autoimmune Disease Recruitment opened
- Notable: YTS109 Cell in R/R Autoimmune Diseases Primary completion pushed from May 19, 2026 to May 19, 2027
- Stopped: Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis Trial terminated
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-11-18 | NCT07946367 Dual-targeting of B & T Cell Pathways Evaluation Trial | Diabetes Free, Inc. new | Phase 1/2 |
| 2026-11-09 | NCT07925619 Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital… | Pharmosa Biopharm Inc. new | Phase 2 |
| 2026-10-30 | NCT07906145 A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases | Shanghai Qilu Pharmaceutical Research and Development Center LTD new | Phase 1 |
| 2026-10-30 | NCT07908108 Cross-cultural Adaptation and Validation of the Localised Scleroderma Quality of Life… | Istituto Giannina Gaslini new | |
| 2026-10-02 | NCT07854483 C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in… | AbelZeta Inc. new | Phase 1 |
| 2026-09-30 | NCT07849673 Improving ILD Screening in Patients With RA and SSc Using EHR-Embedded CDS and PRO Tools | Foundation for Advancing Science Technology Education and Research new | |
| 2026-09-15 | NCT07821398 Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung… | Bastiaan Driehuys new | Phase 2 |
| 2026-09-14 | NCT07817160 Pelvic Floor Dysfunction in Pulmonary Systemic Sclerosis | Biruni University new | |
| 2026-09-08 | NCT07806045 Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement | Qiubai Li new | Early Phase 1 |
| 2026-08-21 | NCT07778446 A Study to Test CRT-402 in Refractory Autoimmune Disease | Myeloid Therapeutics new | Phase 1/2 |
Active trials by phase
| Early Phase 1 | 23 | |
| Phase 1 | 41 | |
| Phase 1/2 | 22 | |
| Phase 2 | 38 | |
| Phase 2/3 | 4 | |
| Phase 3 | 13 | |
| Phase 4 | 5 |
Not charted: 113 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
Assistance Publique - Hôpitaux de Paris (9) · Assiut University (6) · University Hospital, Strasbourg, France (6) · Beijing GoBroad Hospital (5) · Peking University Third Hospital (5) · China Immunotech (Beijing) Biotechnology Co., Ltd. (4) · Hacettepe University (4) · Institute of Hematology & Blood Diseases Hospital, China (4) · The Children's Hospital of Zhejiang University School of Medicine (4) · University Hospital, Toulouse (4)
Get alerts when Scleroderma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.